The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
TAP deficiency syndrome
Open accessAbstract
Bare lymphocyte syndrome (BLS) is characterized by a severe down-regulation of HLA class I and/or class II molecules. In type 1 BLS the defect is confined to HLA class I molecules, while in type 2 BLS HLA class II molecules are down-regulated [1]. Characterization of 22 patients with type 1 BLS over the last 22 years has revealed the existence of several clinically and immunologically distinct disease subsets [1–20]. In this review we will focus on a recently characterized group of patients with a distinct disease phenotype due to a defective TAP complex, the peptide transporter complex associated with antigen presentation [2–15]. We will describe clinical manifestations and immunological findings of patients suffering from TAP deficiency syndrome, and discuss the differential diagnosis and therapeutic options. HLA class I molecules are highly polymorphic transmembrane glycoproteins expressed to variable levels on the surface of all nucleated cells in the body. HLA class I molecules have the dual role of presenting intracellular antigenic peptides to cytotoxic T lymphocytes (CTL), and modulating the activity of cells bearing HLA class I binding receptors, such as natural killer (NK) cells and γδ T cells [21–24] (Fig. 1). Failure to express HLA class I molecules on the surface of malignant or virus-infected cells sensitizes them for lysis by NK and γδ T cells [25]. Furthermore, presentation of self-peptides via HLA class I molecules is critical for the selection of cytotoxic T cells in the thymus [26]. 1, Proteasome-dependent generation of antigenic peptides from newly synthesized proteins; 2, translocation of peptides from the cytosol into the endoplasmic reticulum (ER) by the transporter associated with antigen presentation (TAP); 3, loading of peptides onto MHC class I/β2-microglobulin (β2-M) complexes; 4, peptide/MHC class I/β2-M complexes leave the ER and enter the Golgi apparatus, where they undergo maturation; 5, expression of peptide/MHC class I/β2-M complexes on the cell surface. Interaction of class I molecules with either NK cells, γδ T cells (TCRγδ) or CD8+ CTL (CD8/TCRαβ) via NK receptors or the T cell receptor. During biosynthesis, HLA class I molecules associate with 8–11 amino acid long peptides and β2-microglobulin (β2-M) within the lumen of the endoplasmic reticulum (ER) (as reviewed in [−2627]). Different HLA class I alleles bind to different sets of peptides, most of which are derived from the degradation of cytosolic proteins by a large proteolytic complex called the proteasome. Translocation of peptides derived from degradation of cytosolic proteins into the ER is mediated by the transporter associated with antigen presentation (TAP), a member of the ATP-binding cassette (ABC) superfamily of transporters. TAP is a heterodimer and consists of two subunits, TAP1 and TAP2, which are encoded in the class II region of the HLA locus on chromosome 6. Deletion or mutation of either or both TAP1 and TAP2 proteins severely impairs the translocation of peptides into the ER. The role of TAP1 and TAP2 in peptide presentation is shown in Fig. 1. Before binding peptides, newly synthesized HLA class I molecules are retained in the ER through interactions with the molecular chaperones calnexin, calreticulin, and ERp57, as well as with the glycoprotein tapasin [28–31]. In the absence of a peptide ligand, the HLA class I/β2-M complex is unstable, resulting in dissociation of β2-M and unfolding of HLA class I molecules [32,33]. Hence, any defect which impairs the translocation of peptides into the ER results in reduced surface expression of HLA class I molecules. Patients with a defective HLA class I presentation pathway can be identified by measuring HLA class I surface expression on peripheral blood mononuclear cells (PBMC) by fluorescence-activated cell sorter analysis (FACS) [2]. Since the first report by Touraine in 1978, 22 patients with type 1 BLS have been identified worldwide [1–20]. Three groups of patients can be differentiated on clinical and immunological grounds: Group 1. This group includes patients with the most severe disease phenotype with recurrent severe bacterial, fungal and parasitic infections from the age of 4–5 months of life. Only four patients have been described so far, all of whom died within the first 3 years of life from infectious complications [1,17,18]. Besides a severe down-regulation of HLA class I and β2-M on the cell surface, complete lack of antibody production was demonstrated in these patients. Defective transcription of β2-M and HLA class I was ruled out, as both proteins were detectable in the patients' serum. Since patients were heterozygous for the HLA haplotype, it is unlikely that the gene(s) responsible for the HLA class I down-regulation was encoded within the HLA locus. Group 2. Patients in this group of type 1 BLS are completely asymptomatic. One family with two affected children has been described so far [19]. Down-regulation of HLA class I and β2-M surfa
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
In search of the ‘missing self’: MHC molecules and NK cell recognition
Ljunggren, H.-G., & Kärre, K. (1990) · Immunology Today · doi:10.1016/0167-5699(90)90097-s · Cited by 2,687
Cited by
Cancer Immune Evasion Through Loss of MHC Class I Antigen Presentation
Dhatchinamoorthy, K., Colbert, J. D., & Rock, K. L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.636568 · Cited by 1,077
British Thoracic Society guideline for non-CFbronchiectasis
Pasteur, M. C., Bilton, D., Hill, A. T., & on behalf of the British Thoracic Society Bronchiectasis (non-CF) Guideline Group (2010) · Thorax · doi:10.1136/thx.2010.136119 · Cited by 1,046
HLA-E-expressing pluripotent stem cells escape allogeneic responses and lysis by NK cells
Gornalusse, G. G., Hirata, R. K., Funk, S. E., Riolobos, L., Lopes, V. S., Manske, G., Prunkard, D., Colunga, A. G., Hanafi, L.-A., Clegg, D. O., et al. (2017) · Nature Biotechnology · doi:10.1038/nbt.3860 · Cited by 639
Leone, P., Shin, E.-C., Perosa, F., Vacca, A., Dammacco, F., & Racanelli, V. (2013) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt184 · Cited by 553
Practice parameter for the diagnosis and management of primary immunodeficiency
Bonilla, F. A., Bernstein, I. L., Khan, D. A., Ballas, Z. K., Chinen, J., Frank, M. M., Kobrynski, L. J., Levinson, A. I., Mazer, B., Nelson, R. P., et al. (2005) · Annals of Allergy, Asthma & Immunology · doi:10.1016/s1081-1206(10)61142-8 · Cited by 521
Metadata
- Authors
- Gadola, S. D., Moins-Teisserenc, H. T., Trowsdale, J., Gross, W. L., & Cerundolo, V
- Venue
- Clinical and Experimental Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2000-08
- Volume
- 121
- Issue
- 2
- Pages
- 173-178
- ISSN
- 0009-9104 (ISSN-L)
- 1365-2249
- OpenAlex
- W1642772401
- Cited by
- 201
- References
- 1
- FWCI
- 2.03
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: TAP deficiency syndrome. https://app.cochat.ai/papers/10.1046/j.1365-2249.2000.01264.x
- The paper
- Gadola, S. D., Moins-Teisserenc, H. T., Trowsdale, J., Gross, W. L., & Cerundolo, V. (2008). TAP deficiency syndrome. Clinical and Experimental Immunology. https://doi.org/10.1046/j.1365-2249.2000.01264.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.